Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem
to treat bacterial infections, including those due to multi-drug resistant bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)